187,100
-0.21%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hugel
Its shares trade on KOSDAQ under the ticker 145020.KQ. It has been listed since 24 December 2015. In the fiscal year to 31 December 2025, it reported revenue of ₩425.11bn and net income of ₩140.87bn. At that date it held total assets of ₩1.08trn and shareholders' equity of ₩950.26bn.
Hugel, Inc. engages in the manufacture and sale of biopharmaceuticals based on clostridium botulinum. The company is headquartered in Chuncheon, Gangwon-Do. The company went IPO on 2015-12-24. The firm's product portfolio consists of botulinum toxins which used for treatment of benign essential blepharospasm and temporary improvement of moderate to severe glabellar lines including 50 unit types, 100 unit types and 200unit types; hyaluronic acid (HA) fillers which used for temporary removal of facial wrinkles including the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A and the chaeum VOLUS 20A; wellages, blue roses and other cosmetics. The firm sells its products in domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 Dec 2015
- Website
- hugel.co.kr ↗
Leadership
Pay as last reported
- Mr. Sun Wu GwonVice President, since 2021
- Mr. Seon Ho HanVice President
- Mr. Chang Jin LeeVice President, since 2021₩4.68bn
- Mr. Hyeong Jin MoonVice President
- Mr. Hyeon JangManaging Director
- Mr. Min Jong KangManaging Director
- Ms. Ji Hye nohManaging Director
- Mr. Yeong Man YooManaging Director
- Ms. Gyeong Ye ChoAssistant Managing Director
- Mr. Sang Jun ChoAssistant Managing Director
- Mr. Chang Wu HaAssistant Managing Director
- Ms. Hyo Jin JeonAssistant Managing Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hugel Inc manufactures biopharmaceuticals using clostridium botulinum for blepharospasm treatment and glabellar lines.
- Hugel Inc offers 50, 100, and 200 unit types of botulinum toxins for medical use.
- Hugel Inc sells hyaluronic acid fillers like Chaeum Premium No.1 to No.4 and MID 20A in domestic and overseas markets.
Weaknesses
- Hugel Inc's product range includes only botulinum toxins and HA fillers without other biopharmaceuticals.
- Hugel Inc's domestic market focus may limit international growth opportunities.
- Hugel Inc's product portfolio lacks diversity beyond cosmetic and medical treatments.
Opportunities
- Hugel Inc can expand its botulinum toxin products to new markets in Asia and Europe.
- Hugel Inc can leverage its Chaeum Premium line for new cosmetic applications.
- Hugel Inc can explore partnerships for hyaluronic acid filler distribution in North America.
Threats
- Hugel Inc faces competition from established biotech firms in the Health Care sector.
- Hugel Inc must comply with strict regulations for biopharmaceutical manufacturing in KR.
- Hugel Inc's reliance on clostridium botulinum may lead to supply chain vulnerabilities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.